India · Delayed Price · Currency is INR Fredun Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2027
-
Q1 FY 2027 saw revenue surge 90% YoY to INR 228.25 crores, with net profit up 95% and margins improving. Growth is driven by new age brands, Pet Care, and Gx, with 30%-50% annual growth expected in key segments. Major CapEx and product launches are planned.
Fiscal Year 2026
-
Q4 and FY 2026 saw robust revenue and profit growth, driven by strong performance in new age businesses like pet care and mobility, with margins expanding due to higher-value products and economies of scale. The company targets 25%-30% top-line growth for FY 2027 and expects PAT margins to reach 10%-12% in the coming years.
-
Q3 and nine-month results showed strong revenue and profit growth, with significant margin expansion and robust performance from both legacy and New Age businesses. Management expects continued growth, with New Age segments set to comprise over half of revenue by 2029-30.
-
Strong Q2 and H1 FY26 results with double-digit revenue and profit growth, driven by expansion in pet care, nutraceuticals, and mobility. Strategic acquisitions and manufacturing expansion support long-term growth, with positive cash flow and robust guidance for the coming years.
-
Q1 FY 2026 saw revenue rise 52% and net profit 64% year-on-year, driven by strong branded generics and pet care growth. The company targets to double revenue and PAT in 3-4 years, with new age business expected to contribute over half of future revenue.